Lovenox Injection
Product Images NDC 0075-0621

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Lovenox (NDC 0075-0621). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (5017a927 2a24 4f27 89f9 27c805bf7d59 01)

An instructional illustration showing two hands pulling apart components of a syringe, likely demonstrating how to detach the syringe from its packaging or assembly before use.*

FDA Label Image

Figure B (5017a927 2a24 4f27 89f9 27c805bf7d59 02)

An instructional illustration showing a hand administering an injection with a syringe, directed by an arrow indicating the motion away from the injection site. The image is related to the administration technique of Lovenox, an anticoagulant medication by sanofi-aventis U.S. LLC.*

FDA Label Image

Figure C (5017a927 2a24 4f27 89f9 27c805bf7d59 03)

An instructional illustration showing a hand holding a syringe with an arrow indicating the removal of the needle cover. This image demonstrates part of the preparation process for administering an injection, relevant to the Lovenox product.*

FDA Label Image

Figure D (5017a927 2a24 4f27 89f9 27c805bf7d59 04)

An instructional illustration showing a gloved hand holding a syringe with a blue arrow indicating the plunger being pushed, likely demonstrating proper technique for preparing or administering an injection.*

FDA Label Image

Figure E (5017a927 2a24 4f27 89f9 27c805bf7d59 05)

An instructional illustration showing a hand pressing down on the lid of a sharps disposal container marked with a red biohazard symbol, indicating proper disposal of a used syringe or needle.*

FDA Label Image

Chemical Structure (5017a927 2a24 4f27 89f9 27c805bf7d59 06)

Chemical structure diagram showing the molecular arrangement of an active ingredient associated with Lovenox (enoxaparin sodium), featuring repeating sugar units with sodium carboxylate (COONa), hydroxyl (OH), and amino (NHR2) groups, indicating the polysaccharide nature of the molecule.*

FDA Label Image

Chemical Structure (5017a927 2a24 4f27 89f9 27c805bf7d59 07)

Chemical structure diagram showing the molecular structure of the active ingredient in Lovenox as indicated by the image features. The structure includes sugar rings with various functional groups attached, typical of low molecular weight heparins like enoxaparin sodium.*

FDA Label Image

Figure 1 (5017a927 2a24 4f27 89f9 27c805bf7d59 08)

A forest plot chart showing relative risk comparisons between UFH and Enoxaparin (Lovenox) across various patient subgroups, including sex, age, infarct location, diabetes status, prior MI, fibrinolytic agent, time to treatment, and PCI within 30 days. The chart includes the number of patients, percentage risk for UFH and Enoxaparin, and reduction in risk, illustrating Enoxaparin's relative efficacy across these subgroups.*

FDA Label Image

Figure 2 (5017a927 2a24 4f27 89f9 27c805bf7d59 09)

A Kaplan-Meier curve chart showing the hazard distribution function over 30 days for time to death or myocardial reinfarction, comparing Enoxaparin and UFH treatments. The graph includes a smaller inset displaying the comparison over one year. Data points and log-rank test p-values are indicated.*

FDA Label Image

Figure (5017a927 2a24 4f27 89f9 27c805bf7d59 10)

An instructional diagram depicting a syringe labeled Lovenox before and after use. The 'Before Use' image shows the plunger rod, needle with needle cap, and body filled with medication. The 'After Use' image shows the plunger rod fully depressed and the syringe covered by a protective sleeve over the needle area.*

FDA Label Image

Figure A (5017a927 2a24 4f27 89f9 27c805bf7d59 11)

An instructional illustration showing the components included with Lovenox prefilled syringes. It depicts a prefilled syringe with a needle cap, a cotton ball or gauze, a small adhesive bandage, an alcohol wipe, and a sharps disposal container, indicating proper materials for injection and disposal.*

FDA Label Image

Figure B (5017a927 2a24 4f27 89f9 27c805bf7d59 12)

An instructional illustration showing a person removing a protective film from a Lovenox prefilled syringe. The hands are positioned to peel away the backing, revealing the syringe barrel and plunger inside the packaging device.*

FDA Label Image

Figure C (5017a927 2a24 4f27 89f9 27c805bf7d59 13)

An instructional line drawing of a syringe with an attached needle cover and a plunger, showing an area labeled for the expiration date. The syringe is designed for precise dosing, likely related to the Lovenox injectable product by sanofi-aventis U.S. LLC.*

FDA Label Image

Figure D (5017a927 2a24 4f27 89f9 27c805bf7d59 14)

An illustration showing a syringe filled with a clear liquid. The syringe is labeled to indicate the liquid inside is clear, depicting the medication in the syringe ready for administration.*

FDA Label Image

Figure E (5017a927 2a24 4f27 89f9 27c805bf7d59 15)

An instructional diagram showing the front torso area, highlighting two rectangular patches placed on the left and right sides of the abdomen. This likely represents application sites for a medication or patch related to Lovenox administration.*

FDA Label Image

Figure F (5017a927 2a24 4f27 89f9 27c805bf7d59 16)

An instructional illustration showing a hand placing a small adhesive patch on the skin near the waistline, indicating the application site for a transdermal or topical medication patch.*

FDA Label Image

Figure G (5017a927 2a24 4f27 89f9 27c805bf7d59 17)

Illustration showing the removal of a protective cap from a Lovenox prefilled syringe. One hand holds the syringe while the other hand pulls the cap off by applying opposite directional forces as indicated by arrows. This image guides the preparation step before injection.*

FDA Label Image

Figure H (5017a927 2a24 4f27 89f9 27c805bf7d59 18)

An instructional illustration showing a hand holding a prefilled syringe with the thumb pressing down on the plunger. A downward arrow indicates the direction for setting the dose, and the syringe features measurement markings with a label 'Set your dose.' The image demonstrates dose adjustment for Lovenox injection.*

FDA Label Image

Figure I (5017a927 2a24 4f27 89f9 27c805bf7d59 19)

An instructional diagram showing a hand pulling up the waistband of pants or clothing, likely demonstrating how to access the injection site on the abdomen for Lovenox administration.*

FDA Label Image

Figure J (5017a927 2a24 4f27 89f9 27c805bf7d59 20)

An instructional diagram showing the correct injection technique for Lovenox. The image depicts a hand holding a syringe at a 90-degree angle to the skin of the abdomen, indicating subcutaneous administration with an arrow showing direction toward the injection site.*

FDA Label Image

Figure K (5017a927 2a24 4f27 89f9 27c805bf7d59 21)

An instructional illustration showing a hand administering an injection into the abdomen using a prefilled syringe. Another hand is gently pinching the skin near the injection site. The syringe is being inserted at an angle indicated by an arrow, demonstrating proper injection technique.*

FDA Label Image

Figure L (5017a927 2a24 4f27 89f9 27c805bf7d59 22)

Instructional illustration showing a hand administering an injection with a prefilled syringe to the abdomen area near the waistline. The image guides on the site or method of subcutaneous injection, typically associated with self-administration of Lovenox (enoxaparin sodium). An arrow indicates the direction of syringe insertion.*

FDA Label Image

Figure M (5017a927 2a24 4f27 89f9 27c805bf7d59 23)

An instructional illustration shows a hand holding a Lovenox prefilled syringe with a protective sleeve. An arrow and the word "CLICK" indicate a step in syringe use or activation, highlighting the protective sleeve on the syringe.*

FDA Label Image

Figure N (5017a927 2a24 4f27 89f9 27c805bf7d59 24)

An instructional illustration showing a hand holding a Lovenox syringe and disposing of the needle cap into a labeled sharps disposal container.*

FDA Label Image

Principal Display Panel (30 mg/0.3 mL Syringe Carton)

Lovenox 30 mg/0.3 mL carton label for enoxaparin sodium injection, single dose syringes with automatic safety device for subcutaneous injection. The box contains ten 0.3 mL syringes. The label includes dosage and administration instructions, safety warnings, storage information, and is branded by sanofi-aventis U.S. LLC.*

FDA Label Image

Principal Display Panel (40 mg/0.4 mL Syringe Carton)

Lovenox 40 mg/0.4 mL injection packaging label for subcutaneous use. The label indicates the product contains ten 0.4 mL single-dose syringes with an automatic safety device. The labeler is sanofi-aventis U.S. LLC, and storage instructions and warnings are included on the box. The packaging features the Lovenox logo with enoxaparin sodium injection designation.*

FDA Label Image

Principal Display Panel (60 mg/0.6 mL Syringe Carton)

Packaging label for Lovenox 60 mg/0.6 mL injection (enoxaparin sodium) by sanofi-aventis U.S. LLC. The box contains ten 0.6 mL single-dose syringes with automatic safety devices, intended for subcutaneous use. The label includes storage instructions, usage warnings, and a barcode. The design features an orange and white color scheme with the brand and generic names prominently displayed.*

FDA Label Image

Principal Display Panel (80 mg/0.8 mL Syringe Carton)

Packaging label for Lovenox (enoxaparin sodium) injection, 80 mg/0.8 mL strength. The label indicates subcutaneous use and contains ten 0.8 mL single-dose syringes with automatic safety devices. Manufactured by sanofi-aventis U.S. LLC, the label also includes storage instructions and a barcode, with clear branding and dosage information.*

FDA Label Image

Principal Display Panel (100 mg/1 mL Syringe Carton)

Packaging label for Lovenox (enoxaparin sodium) injection, 100 mg/mL, intended for subcutaneous use. The label indicates ten 1 mL single-dose syringes with automatic safety devices. Labeler is sanofi-aventis U.S. LLC, with storage instructions and dosage information included. The packaging is a foldable carton primarily white with black and blue text.*

FDA Label Image

Principal Display Panel (300 mg/3 mL Vial Carton)

Packaging label for Lovenox (enoxaparin sodium) injection, 300 mg/3 mL (100 mg/mL). The label shows the product name, strength, and dosage form as an injectable solution for subcutaneous or intravenous use. It includes storage instructions, dosing reference, manufacturer information (sanofi-aventis U.S. LLC), and barcode. The package contains one 3 mL multiple-dose vial.*

FDA Label Image

Principal Display Panel (120 mg/0.8 mL Syringe Carton)

Packaging label for Lovenox (enoxaparin sodium) injection, 120 mg/0.8 mL. The label indicates this product is for subcutaneous use and includes ten 0.8 mL single-dose syringes with an automatic safety device. The labeler is sanofi-aventis U.S. LLC, with the product manufactured in Singapore. Storage instructions and warning about keeping out of reach of children are included.*

FDA Label Image

Principal Display Panel (150 mg/1 mL Syringe Carton)

Lovenox 150 mg/mL (enoxaparin sodium) injection carton for subcutaneous use. The package contains ten 1 mL single-dose syringes with an automatic safety device. Labeler is sanofi-aventis U.S. LLC. The carton includes storage instructions and a barcode on the back panel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.